Recent clinical research has revealed that GLP-1 receptor agonists have what scientists call a "hypodipsic effect"essentially, they suppress your natural desire to drink water
These are published, peer-reviewed findings from trials like SURPASS-CVOT, SURMOUNT-OSA, SYNERGY-NASH, and SUMMIT
Every line item is reviewed with you before you commit
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
Join hundreds of churches already growing with SmartChurch
After each dose increase, you may experience a mini-return of side effects, usually milder than what you experienced initially
.webp)
